Abstract: The present invention pertains to the treatment of proliferative diseases, such as cancer. In particular, the invention describes a novel combination therapy strategy, comprising a Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, an Inhibitor of ?B (I?B) Kinase (IKK)/Nuclear Factor ?B (NF?B)-signaling inhibitor, and a B-cell lymphoma 2 (BCL-2) inhibitor for the treatment and/or prevention of proliferative diseases, such as cancer. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

Abstract: Various embodiments illustrated and described herein include one or more of systems, methods, and software providing for configurable metrics and metric visualizations with regard to company data. Such embodiments provide flexibility to users in defining metrics, such as Key Performance Indicators (KPI), and dashboard views. One such embodiment includes receiving a dashboard view request from a requestor. A dashboard configuration may then be retrieve from a database. The dashboard configuration typically includes various data elements that define either directly or by reference to other data and graphical elements from which a dashboard visualization can be rendered. The various data elements and graphical elements generally are user configurable and standardized to be interchangeable in defining and generating dashboard visualization based on underlying operational data of an organization.

Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.

Abstract: Various embodiments illustrated and described herein include one or more of systems, methods, and software providing for configurable metrics and metric visualizations with regard to company data. Such embodiments provide flexibility to users in defining metrics, such as Key Performance Indicators (KPI), and dashboard views. One such embodiment includes receiving a dashboard view request from a requestor. A dashboard configuration may then be retrieve from a database. The dashboard configuration typically includes various data elements that define either directly or by reference to other data and graphical elements from which a dashboard visualization can be rendered. The various data elements and graphical elements generally are user configurable and standardized to be interchangeable in defining and generating dashboard visualization based on underlying operational data of an organization.

Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.

Abstract: A method of path planning for a working resource to access storage bins in a warehouse, the warehouse comprising a plurality of storage bins, the warehouse being divided into a set of activity areas, each activity area comprising a number of the bins of the warehouse; the method comprising the following steps: Selecting one out of a set of activities of a working resource in the warehouse; selecting a sort sequence which is associated with the selected activity, the sort sequence defining a path through the activity area the working resource has to follow when accessing the bins; determining, based on the selected activity area and the selected sort sequence, the path through the activity area to the bins.

Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.

Abstract: The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent, or a chemotherapeutic agent to the patient. The invention further provides methods for identifying a cancer patient that may selectively benefit from the administration of a chemotherapeutic agent, or the administration of a MK2 inhibitor or the combination of a MK2 inhibitor and a chemotherapeutic agent, requiring the steps of determining the activation or inactivation of the MK2 signaling pathway. The invention additionally provides methods and kits for diagnosing a chemotherapy-sensitive or chemotherapy-resistant cancer in a subject that require the step of (or reagents for) determining the activation or inactivation of the MK2 signaling pathway.

Abstract: A method of path planning for a working resource to access storage bins in a warehouse, the warehouse comprising a plurality of storage bins, the warehouse being divided into a set of activity areas, each activity area comprising a number of the bins of the warehouse; the method comprising the following steps: Selecting one out of a set of activities of a working resource in the warehouse; selecting a sort sequence which is associated with the selected activity, the sort sequence defining a path through the activity area the working resource has to follow when accessing the bins; determining, based on the selected activity area and the selected sort sequence, the path through the activity area to the bins.

Abstract: Methods and apparatuses enable generation of a managed space layout model defining permissible pathways for travel through the managed space. Each permissible pathway can be defined as a line segment or an edge bounded by coordinate pairs. Items and locations within the managed space are associated with permissible pathways, which association defines how the items/locations can be reached via travel through the managed space. The information can be saved as a network of nodes, which defines the intersection of the permissible pathways and includes information about the pathways. With the layout model, a path can be determined through the managed space to accomplish work in the managed space. The layout data allows a path distance to be calculated for a given work task that involves travel through the managed space.

Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders.

Abstract: An Engineered Labor Standards (“ELS”) scheduling system prepares preliminary estimates of task durations based on a subset of the conditions affecting task duration, then later prepares adjusted estimates when more information about the conditions becomes available. The actual time a resource spends performing the task is measured, and the estimates and measurements are stored in a database.

Abstract: Methods and apparatuses enable generation of a managed space layout model defining permissible pathways for travel through the managed space. Each permissible pathway can be defined as a line segment or an edge bounded by coordinate pairs. Items and locations within the managed space are associated with permissible pathways, which association defines how the items/locations can be reached via travel through the managed space. The information can be saved as a network of nodes, which defines the intersection of the permissible pathways and includes information about the pathways. With the layout model, a path can be determined through the managed space to accomplish work in the managed space. The layout data allows a path distance to be calculated for a given work task that involves travel through the managed space.

Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.

Abstract: A system and method are provided for planned transportation cross-docking. A predetermined route for transportation of goods from a source location to an intermediate location to a destination location is provided. A document associated with goods is generated. The document indicates the predetermined route and includes cross-docking at the intermediate location.